Yannick Van Herck
Overview
Explore the profile of Yannick Van Herck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Karras P, Bordeu I, Pozniak J, Nowosad A, Pazzi C, Van Raemdonck N, et al.
Nature
. 2022 Sep;
610(7930):190-198.
PMID: 36131018
Although melanoma is notorious for its high degree of heterogeneity and plasticity, the origin and magnitude of cell-state diversity remains poorly understood. Equally, it is unclear whether growth and metastatic...
12.
Mennens F, Van Herck Y, Sciot R, Vanden Bempt I, Boecxstaens V, Garmyn M, et al.
Melanoma Res
. 2022 Sep;
32(6):428-439.
PMID: 36125893
Phenotype switching is an emerging concept in melanoma research and deals with the cancer cell plasticity. In this paper, we present five cases of patients with metastatic malignant melanoma where...
13.
Van Herck Y, Feyaerts A, Alibhai S, Papamichael D, Decoster L, Lambrechts Y, et al.
Lancet Healthy Longev
. 2022 Sep;
2(10):e663-e677.
PMID: 36098020
Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are often diagnosed at a later stage and might receive less (intensive) treatment, which might...
14.
Maria Bosisio F, Van Herck Y, Messiaen J, Bolognesi M, Marcelis L, Van Haele M, et al.
Front Oncol
. 2022 Aug;
12:918900.
PMID: 35992810
Single-cell omics aim at charting the different types and properties of all cells in the human body in health and disease. Over the past years, myriads of cellular phenotypes have...
15.
Antoranz A, Van Herck Y, Bolognesi M, Lynch S, Rahman A, Gallagher W, et al.
Cancer Res
. 2022 Jul;
82(18):3275-3290.
PMID: 35834277
Significance: This study shows that spatial characterization can address the challenge of finding efficient biomarkers, revealing that localization of macrophages and T cells in melanoma predicts patient response to ICI....
16.
Celus W, Oliveira A, Rivis S, Van Acker H, Landeloos E, Serneels J, et al.
Cancer Immunol Res
. 2021 Nov;
10(1):126-141.
PMID: 34815265
Cytotoxic T cell (CTL) infiltration of the tumor carries the potential to limit cancer progression, but their exclusion by the immunosuppressive tumor microenvironment hampers the efficiency of immunotherapy. Here, we...
17.
Kinget L, Bechter O, Punie K, Debruyne P, Brems H, Clement P, et al.
Curr Oncol
. 2021 Aug;
28(5):3227-3239.
PMID: 34449592
In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of patients who would benefit most are lacking. Several tumor...
18.
Metzemaekers M, Cambier S, Blanter M, Vandooren J, de Carvalho A, Malengier-Devlies B, et al.
Clin Transl Immunology
. 2021 May;
10(4):e1271.
PMID: 33968405
Objectives: Emerging evidence of dysregulation of the myeloid cell compartment urges investigations on neutrophil characteristics in coronavirus disease 2019 (COVID-19). We isolated neutrophils from the blood of COVID-19 patients receiving...
19.
Van Herck Y, Antoranz A, Andhari M, Milli G, Bechter O, De Smet F, et al.
Front Oncol
. 2021 Apr;
11:636681.
PMID: 33854972
The state-of-the-art for melanoma treatment has recently witnessed an enormous revolution, evolving from a chemotherapeutic, "one-drug-for-all" approach, to a tailored molecular- and immunological-based approach with the potential to make personalized...
20.
Gadeyne L, Van Herck Y, Milli G, Atak Z, Bolognesi M, Wouters J, et al.
Front Oncol
. 2021 Apr;
11:636057.
PMID: 33842341
The emergence of immune checkpoint inhibitors has dramatically changed the therapeutic landscape for patients with advanced melanoma. However, relatively low response rates and a high incidence of severe immune-related adverse...